medigraphic.com
Boletín Médico del Hospital Infantil de México

2009, Number 4

<< Back Next >>

Bol Med Hosp Infant Mex 2009; 66 (4)

20 years of experience in the management of pregnant women infected by HIV/AIDS at the Instituto Nacional de Perinatologia

Plazola-Camacho NG, Ortiz-Ibarra FJ

Language: Spanish
References: 56
Page: 350-363
PDF size: 161.11 Kb.


ABSTRACT

Introduction. We undertook this study to review the international recommendations and report the experience at the Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes (INPerIER) in the management of pregnant women with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS).
Methods. We reviewed medical records of 200 pregnant women with HIV/AIDS receiving care at INPerIER from 1988-2008 with specific focus on different scenarios of pregnant HIV/AIDS patients and different modes of antiretroviral prophylaxis. Treatment advances are also presented.
Results. The impact of diverse worldwide strategies can serve to decrease perinatal transmission of HIV. We report our experience at INPerIER in demonstrating a decrease in the rate of vertical transmission between 1988 and 1998 to 0%.
Conclusions. Early medical interventions with antiretroviral therapy has allowed us to reduce vertical transmission in pregnant women with HIV/AIDS to ‹2% over a 20-year period and to 0% since 1998.


REFERENCES

  1. Gobttlieb MS, Schorrf R, Schamker HM, et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men. New Engl J Med. 1981; 305: 1425-31.

  2. Centers for Diseases Control: unexplained immunodeficiency and opportunistic infections in infants. MMWR Morb Mortal Wkly Rep. 1982; 31: 665-7.

  3. UNAIDS/WHO. Report on the global HIV/AIDS epidemic. December, 2007.

  4. Panorama epidemiológico del VIH/SIDA e ITS en México. Consejo Nacional para la prevención y control del VIH/SIDA. Noviembre, 2008. Disponible en: www.ssa.gob.mx/censida.

  5. Anderson JR. A guide to the clinical care of women with HIV. País: Ed ATIS Rockville; 2001.

  6. Cashat CM, Villalobos AP, Agüero EW. Infección por VIH en pediatría: prevención, diagnóstico y tratamiento. En: Pérez LM, editor. Manual para la atención del paciente con VIH/SIDA. México: Publicaciones Permanyer; 2005. p. 249-72.

  7. Mofeson LM. Epidemiology and determinants of vertical HIV transmission. Semin Pediatr Infect Dis. 1994; 5: 252-65.

  8. Ortiz IF, Rangel FS. El manejo de la mujer embarazada con infección por el VIH y profilaxis postexposión. En: Pérez LM, editor. Manual para la atención del paciente con VIH/SIDA. México: Publicaciones Permayer; 2005. p. 233-48.

  9. Lawrence RM, Lawrence RA. Breast milk and infection. Clin Perinatol. 2004; 31: 501-28.

  10. Lewis P, Nduati R, Kreiss JK, John GC, Richardson BA, Mbori-Ngacha D, et al. Cell free human immunodeficiency virus type 1 in brast milk. J Infect Dis. 1988; 1771: 34-9.

  11. Nduati RW, John GC, Richardson BA. HIV-1 infected cells in breast milk; association with immunosuppresion and vitamin A deficiency. J Infect Dis. 1995; 172: 1461-8.

  12. Kourtis A, Butera S, Ibegbu C, Belec I, Duerr A. Breast milk and HIV-1 vector of transmission or vehicle of protection? Lancet Infect Dis. 2003; 3: 786-93.

  13. Del Rey PG, Lara SJ, Gómez MA, Arredondo GJL. Prevalencia de indicadores de exposiciòn de exposición e infección aguda para toxoplasma, rubéola, CMV, VIH y hepatitis B en mujeres embarazadas. Ginecol Obstet Mex. 1991; 59: 17-20.

  14. Magis C, Pedrosa L, Soler C, Panebianco S, Loo E, Martínez F. Offering HIV detection to pregnant Mexican women. Conference on global strategies for the prevention of HIV transmission from the mother to infant. USA, Washington DC; 1997. p. 9.

  15. Viani R, Ruiz CJ, López EG, et al. HIV prevalence during pregnancy in Tijuana Baja California. AIDS. 2003; 17: 1113-4.

  16. Coonor EW, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment: Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994; 331: 1173-80.

  17. Conference on global strategies for the prevention of HIV transmission from the mother to infant. USA, Washington DC; 1997.

  18. Conference on global strategies for the prevention of HIV transmission from the mother to infant. Montreal, Canada DC; 1999.

  19. Arredondo-García JL, Ortiz-Ibarra FJ. SIDA de transmisión perinatal: Experiencia del Instituto Nacional de Perinatología. Bol Med Hosp Infant Mex. 1992; 49: 573-9.

  20. Arredondo-García JL, Hernández-Trejo M, Figueroa-Damian R, Ortiz-Ibarra FJ, Ahued-Ahued R. SIDA y embarazo. Ginecol Obstet Mex. 1997; 66: 8-12.

  21. Ortiz-Ibarra FJ. Programa de atención integral del Instituto Nacional de Perinatología para la mujer embarazada infectada por el VIH. En: Uribe P, Magis C, editores. La respuesta mexicana al SIDA: Mejores prácticas. México: CONASIDA/UNISIDA; 2001. p. 186-90.

  22. Ortiz-Ibarra FJ, Casta-Cruz M. Prevención de la transmisión perinatal del VIH: Una meta alcanzable. Bol Med Hosp Infant Mex. 2003; 60: 643-54.

  23. Ortiz-Ibarra FJ. Infección por el VIH/SIDA en el embarazo y la lactancia. Gac Med Mex. 2006; 142: 57-64.

  24. Greenblatt RM, Hessol NA. Epidemiology and natural history of HIV infection in women. En: Anderson JR, editor. A guide to the clinical care of women with HIV. USA: Ed. ATIS Rockville; 2001. p. 1-32.

  25. CDC. Administration of zidovudine during late pregnancy and delivery to prevent perinatal HIV transmission -Thailand 1996-1998. MMWR Morb Mortal Wkly Rep. 1998; 47-8: 151-4.

  26. Dabis F, Msellati P, Meda N, et al. 6 month, efficacy, tolerance and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d Ivory and Burkina Faso: a double-blind placebo-controlled multicentre trial. Lancet. 1999; 353: 786-92.

  27. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomized trial. Lancet. 1999; 12: 1735-44.

  28. Dorenbaum A, Cunningham C, Gelber R, et al. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission. A randomized trial. JAMA. 2002; 288: 189-98.

  29. Martison N, Morris L, Gray G, et al. HIV resistant and transmission following a single dose nevirapine in PMTCT cohort. 11th CROI. February, 2004 (oral abstracts 38).

  30. Moondley J, Moondley D, Pillay K, et al. Pharmacokinetics and antiretroviral activity of lamivudine alone or when co administered with zidovudine in human immunodeficiency virus type 1 infected pregnant woman and the off spring. J Infect Dis. 1988; 178: 1327-33.

  31. The Petra Study Team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa and Uganda (Petra study): a randomized double blind placebo-controlled trial. Lancet. 2002; 359: 1178-86.

  32. Dao H, Mofenson LM, Ekpini R, et al. International recommendations on antirretroviral drugs for treatment oh HIV-infected woman and prevention of mother to-child HIV transmission in resource-limited setting: 2006 update. Am J Obstet Gynecol. 2007; Suppl 9: S42-55.

  33. Fowler M, Lampe M,Jamienson D, et al. Reducing the risk of mother to child human immunodeficiency virus transmission: past successes, current progress and challenges and future directions. Am J Obstet Gynecol. 2007; Suppl 9; S2-9.

  34. Duran AS, Losso MH, Salomon H, Nisdi Perinatal Study Group. Drug resistance among HIV-infected pregnant women receiving antiretroviral for prophylaxis. AIDS. 2007; 21: 199-205.

  35. García PM, Kalish LA, Pitt J, Minkoff H, Quinn TC, Burchett SK, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and risk of perinatal transmission. N Engl J Med. 1994; 331: 1173-80.

  36. Stringer J. Transmisión perinatal del VIH. Resúmenes del XIX Congreso Interamericano de Infectología Pediátrica. Zacatecas, Zacatecas, México; diciembre, 2002.

  37. Thorne C. European Collaborative Study. Antiretroviral therapy and cesarean section to reduce vertical transmission of HIV in Europe. Program and abstracts of the XIII International AIDS Conference; 2000 Julio 9-14; Durban Sudafrica: Abstract MoOrC240.

  38. Shapiro D, Tuomala R, Pollack H, et al. Mother -to-child HIV transmission risk according to antiretroviral therapy, mode of delivery, and viral load in 2 895 US women (PACTG 367). Oral presentation at the 11th Conference on retrovirus and opportunistic infections; 2004 February; San Francisco CA: Abstract; 99.

  39. Duarte G, Read JS, Gonin R. Mode of delivery and postpartum morbidity in latin American and Caribbean countries among women who are infected with human immunodeficiency virus -1: The NICHD international site development initiative (NISDI) perinatal study. Am J Obstet Gynecol. 2006; 195: 215-29.

  40. CENSIDA: Guía para el manejo de las personas que viven con el VIH/SIDA. 4ª ed. 2008. Disponible en: www.salud.gob.mx/conasida

  41. Olivera OA, Anderson LM, Diwan BA, et al. Transplacental effects of 3-azido-2´-3´ dideoxythymidine (AZT): tumorigenicityin mice and genotoxicity in mice and monkey. J Natl Cancer Inst. 1997; 89: 1602-8.

  42. Wilmington NC. Antiretroviral pregnancy registry; 2001 May; Interim report 1/1/89-1/31/01.

  43. Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet. 1999; 354: 1084-9.

  44. Nucleoside exposure in the children of HIV- infected women receiving antiretroviral drugs: absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts. J Acquir Immune Defic Syndr. 2000; 25: 261-8.

  45. Blanche S, Tardieu M, Benhammou V, et al. Mitochondrial dysfunction following perinatal exposure to nucleoside analogues. AIDS. 2006; 20: 1685-90.

  46. FDA/Bristol Myers Squibb issues caution for HIV combination therapy with zerit and videx in pregnant women. FDA Talk Paper; 2001 January 5: 1-3.

  47. Serious adverse events attributed to Nevirapine regiments for postexposures worldwide 1997-2000. MMWR Morb Mortal Wkly Rep. 2001; 49: 1153-6.

  48. Maternal toxicity with continuous Nevirapine in pregnancy: results from PACTG 1022. J AIDS. 2004; 36: 772-6.

  49. Public Health Service Task force. Recommendations for use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV-1V transmission in the United States. Safety and toxicity of individual antiretroviral agents in pregnancy. 2005 November 17; Suppl.

  50. Mirochnick M, Dorenbaum A, Holland D, et al. Cord blood protease inhibitor (PI) concentration following in utero exposure. Pediatr Infect Dis J. 2001; 20: 803-5.

  51. CDC. Revised recommendations for HIV testing for adults, adolescents, and pregnant women in the health -care settings. 2006; 55 RR-14: 1-17.

  52. Jamienson DJ, Clark J, Kourtis AP, et al. Recommendations for human immunodeficiency virus screening, prophylaxis and treatment for pregnant women in the United States. Am J Obstet Gynecol. 2007; Suppl: S26-32.

  53. Roche retira Nelfinavir del Mercado Europeo. EMEA. Agencia española de medicamentos y productos. Roche; 2007. Disponible en : www.gtt-vih.org

  54. Riddler SH, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, et al. Class-Sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2000; 358: 2095-106.

  55. Best B, et al. 15th CROI, Boston 2008, #629; 2 Eley T, et al. ibid, #624.

  56. Figueroa-Medrano L, Figueroa DR, Arreola-Ramírez G, Ortiz-Ibarra FJ, Ahued-Ahued R. Neurologic development among perinatally exposed infants to HIV infected women. En: Monduzzi, editor. Barcelona: International Proceeding Divison; 2002. p. 51-5.




2020     |     www.medigraphic.com